Soleno Therapeutics, Inc. (SLNO)
Health Care ยท Pharmaceutical Preparations
Soleno Therapeutics, Inc. (SLNO) was listed on Nasdaq from November 13, 2014. SentiSense covers Soleno Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Anish Bhatnagar is its chief executive officer. The company reports 182 employees, and its corporate website is www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.
Latest reported results
Soleno Therapeutics Inc. reported revenue of $94.6 million for Q1 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 1 institution reported holding SLNO, with 0 shares worth $0 in aggregate. The largest reported holder was Janus Henderson (Jupiter Topco).
More on SLNO
- SLNO sentiment: whether news and social coverage of Soleno Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- SLNO ownership: institutional holders, insider trades and congressional trades.
- SLNO financials: revenue, net income, operating margin and free cash flow through Q1 FY2026.
Frequently asked questions
What does Soleno Therapeutics, Inc. do?
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases.
What sector is SLNO in?
SentiSense classifies Soleno Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where did SLNO stock trade?
Soleno Therapeutics, Inc. (SLNO) was listed on Nasdaq from November 13, 2014.
Who is the CEO of Soleno Therapeutics, Inc.?
Anish Bhatnagar is the chief executive officer of Soleno Therapeutics, Inc..